Also known as Taltz.
Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.
EBGLYSS shows durable control, less maintenance dosing and reduced topical use; TOGETHER‑PsO biomarker data assess Taltz+Zepbound vs Taltz; Olumiant pediatric alopecia areata results also included.
Combination maintained or deepened psoriasis and psoriatic arthritis responses and reduced systemic inflammation while improving metabolic measures including BMI and HbA1c at one year versus Taltz alone.
Phase 3b TOGETHER‑PsA: combination therapy improved ACR50, MDA, fatigue, function, QoL and cardiometabolic markers; 36‑week primary endpoint met (ACR50+≥10% weight loss 31.7% vs 0.8%).
